Literature DB >> 26291010

Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor.

Kyuichi Kadota1, Jun-Ichi Nitadori2, Hideki Ujiie3, Daniel H Buitrago3, Kaitlin M Woo4, Camelia S Sima4, William D Travis5, David R Jones3, Prasad S Adusumilli6.   

Abstract

INTRODUCTION: We previously reported the prognostic significance of the lung adenocarcinoma immune microenvironment. In this study, we preformed comprehensive analysis of immune markers and their associations with prognosis in patients with lung squamous cell carcinoma.
METHODS: We reviewed surgically resected, solitary lung squamous cell carcinoma patients (n = 485; 1999-2009) who were randomly split into a training cohort (n = 331) and validation cohort (n = 154). We constructed tissue microarrays and performed immunostaining for CD3, CD45RO, CD8, CD4, FoxP3, CD20, CD68, CXCL12, CXCR4, CCR7, interleukin-7 receptor, and interleukin-12 receptor β2. Overall survival (OS) was analyzed using the log-rank test and the Cox proportional hazards model.
RESULTS: Analysis of single immune cell infiltration revealed that high tumor-infiltrating CD10(+) neutrophils were associated with worse prognoses in the training cohort (p = 0.021). Analysis of biologically relevant immune cell combinations identified that patients with high CD10 neutrophil and low CD20(+) lymphocyte had a significantly worse OS (5-year OS, 42%) than those with other combinations of CD10 and CD20 (5-year OS, 62%; p < 0.001); this was confirmed in the validation cohort (p = 0.032). For the multivariate analysis, high CD10/low CD20 immune cell infiltration was an independent predictor of OS in both the training cohort (hazard ratio = 1.61, p = 0.006) and the validation cohort (hazard ratio = 1.75; p = 0.043).
CONCLUSION: High CD10(+)/low CD20(+) immune cell infiltration ratio is a significant prognostic factor of lung squamous cell carcinoma. Immunomodulatory therapy of tumor-specific neutrophil and B-lymphocyte responses may have applicability in the treatment of lung squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26291010      PMCID: PMC4545576          DOI: 10.1097/JTO.0000000000000617

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  51 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

2.  B cells delay neutrophil migration toward the site of stimulus: tardiness critical for effective bacillus Calmette-Guérin vaccination against tuberculosis infection in mice.

Authors:  Tatiana K Kondratieva; Elvira I Rubakova; Irina A Linge; Vladimir V Evstifeev; Konstantin B Majorov; Alexander S Apt
Journal:  J Immunol       Date:  2009-12-18       Impact factor: 5.422

3.  Human neutrophils facilitate tumor cell transendothelial migration.

Authors:  Q D Wu; J H Wang; C Condron; D Bouchier-Hayes; H P Redmond
Journal:  Am J Physiol Cell Physiol       Date:  2001-04       Impact factor: 4.249

4.  Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments.

Authors:  M Mazumdar; J R Glassman
Journal:  Stat Med       Date:  2000-01-15       Impact factor: 2.373

5.  Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.

Authors:  Rebecca P Petersen; Michael J Campa; Justin Sperlazza; Debbi Conlon; Mary-Beth Joshi; David H Harpole; Edward F Patz
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

6.  Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.

Authors:  Kyuichi Kadota; Jonathan Villena-Vargas; Jun-Ichi Nitadori; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli
Journal:  Ann Surg Oncol       Date:  2015-01-22       Impact factor: 5.344

7.  Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression.

Authors:  Inbal Mishalian; Rachel Bayuh; Liran Levy; Lida Zolotarov; Janna Michaeli; Zvi Gregorio Fridlender
Journal:  Cancer Immunol Immunother       Date:  2013-10-04       Impact factor: 6.968

8.  Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer.

Authors:  Andreas Trojan; Mirjana Urosevic; Reinhard Dummer; Robin Giger; Walter Weder; Rolf A Stahel
Journal:  Lung Cancer       Date:  2004-05       Impact factor: 5.705

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  Preoperative neutrophil/lymphocyte ratio predicts overall survival but does not predict recurrence or cancer-specific survival after curative resection of node-positive colorectal cancer.

Authors:  Lucy Jankova; Owen F Dent; Charles Chan; Pierre Chapuis; Stephen J Clarke
Journal:  BMC Cancer       Date:  2013-10-01       Impact factor: 4.430

View more
  26 in total

Review 1.  Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity.

Authors:  Sara Pilotto; Miguel Angel Molina-Vila; Niki Karachaliou; Luisa Carbognin; Santiago Viteri; Maria González-Cao; Emilio Bria; Giampaolo Tortora; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2015-12

2.  Neoadjuvant chemoradiotherapy of rectal carcinoma : Baseline hematologic parameters influencing outcomes.

Authors:  Miroslav Hodek; Igor Sirák; Alexander Ferko; Július Örhalmi; Eva Hovorková; Dimitar Hadži Nikolov; Petr Paluska; Jindřich Kopecký; Jiří Petera; Milan Vošmik
Journal:  Strahlenther Onkol       Date:  2016-06-06       Impact factor: 3.621

Review 3.  CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.

Authors:  Masha Zeltsman; Jordan Dozier; Erin McGee; Daniel Ngai; Prasad S Adusumilli
Journal:  Transl Res       Date:  2017-04-26       Impact factor: 7.012

Review 4.  Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.

Authors:  Hua Zheng; Masha Zeltsman; Marjorie G Zauderer; Takashi Eguchi; Raj G Vaghjiani; Prasad S Adusumilli
Journal:  Immunotherapy       Date:  2017-09       Impact factor: 4.196

Review 5.  Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation.

Authors:  Jonathan E Schoenhals; Steven N Seyedin; Clark Anderson; Eric D Brooks; Yun R Li; Ahmed I Younes; Sharareh Niknam; Ailin Li; Hampartsoum B Barsoumian; Maria Angelica Cortez; James W Welsh
Journal:  Transl Lung Cancer Res       Date:  2017-04

6.  Regional Emphysema Score Predicting Overall Survival, Quality of Life, and Pulmonary Function Recovery in Early-Stage Lung Cancer Patients.

Authors:  Jie Dai; Ming Liu; Stephen J Swensen; Shawn M Stoddard; Jason A Wampfler; Andrew H Limper; Gening Jiang; Ping Yang
Journal:  J Thorac Oncol       Date:  2017-01-23       Impact factor: 15.609

Review 7.  Driving CARs on the uneven road of antigen heterogeneity in solid tumors.

Authors:  Nan Chen; Xiaoyu Li; Navin K Chintala; Zachary E Tano; Prasad S Adusumilli
Journal:  Curr Opin Immunol       Date:  2018-03-16       Impact factor: 7.486

Review 8.  Surgical immune interventions for solid malignancies.

Authors:  Masha Zeltsman; Marissa Mayor; David R Jones; Prasad S Adusumilli
Journal:  Am J Surg       Date:  2016-07-18       Impact factor: 2.565

Review 9.  Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

Authors:  Stefan Kiesgen; Leonardo Chicaybam; Navin K Chintala; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2017-10-26       Impact factor: 15.609

10.  Neutrophil-to-Lymphocyte Ratio on Admission is an Independent Risk Factor for the Severity of Neurological Impairment at Disease Onset in Patients with a First Episode of Neuromyelitis Optica Spectrum Disorder.

Authors:  Yongyan Zhou; Haojie Xie; Yi Zhao; Jinwei Zhang; Yanfei Li; Ranran Duan; Yaobing Yao; Yanjie Jia
Journal:  Neuropsychiatr Dis Treat       Date:  2021-05-18       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.